Prophylactic Cranial Irradiation (PCI) and Brain MRI Surveillance versus Brain MRISurveillance Alone in Patients with Limited-Stage Small Cell Lung Cancer Achieving Complete Remission (CR) of tumor after Chemoradiotherapy: a Multicenter Prospective Randomized Study

Author:

Chen Mengyuan1,Li Runhua1,Kong Yue1,Shi Lei1,Wang Jing1,Wang Yuezhen1,Xu Yujin1,Ji Yongling1,Hu Xiao1

Affiliation:

1. Zhejiang Cancer Hospital

Abstract

Abstract Background Prophylactic cranial irradiation (PCI) is part of standard care in limited-stage small cell lung cancer (SCLC) at present. As evidence from retrospective studies increases, the benefits of PCI for limited-stage SCLC are being challenged. Methods A multicenter, prospective, randomized controlled study was designed. The key inclusion criteria were: histologically or cytologically confirmed small cell carcinoma, age ≥ 18 years, KPS ≥ 80, limited stage defined as tumor confined to one side of the chest including ipsilateral hilar, bilateral mediastinum, bilateral supraclavicular lymph nodes, patients have received definitive thoracic radiotherapy (regardless of the dose-fractionation of radiotherapy used) and chemotherapy, evaluated as complete remission (CR) of tumor 4–6 weeks after the completion of chemo-radiotherapy. Eligible patients will be randomly assigned to two arms: (1) PCI and brain MRI follow-up arm, receiving PCI (2.5Gy qd to a total dose of 25Gy in two weeks) followed by brain MRI follow-up once every three months for two years; (2) brain MRI surveillance alone arm, undergoing brain MRI surveillance once every three months for two years. The primary objective was to compare the 2-year brain metastasis-free survival (BMFS) rates between the two arms. Secondary objectives included 2-year overall survival (OS) rates, intra-cranial failure patterns, 2-year progression-free survival rates and neurotoxicity. In case of brain metastasis (BM) detected during follow-up, patients meeting the eligibility criteria will receive stereotactic radiosurgery (SRS). Discussion Based on our post hoc analysis of a prospective study, we hypothesize that in limited-stage SCLC patients with CR after definitive chemoradiotherapy, and ruling out of BM by MRI, it would be feasible to use brain MRI surveillance and omit PCI in these patients. If BM is detected during follow-up, treatment with SRS or whole brain radiotherapy (WBRT) does not appear to have a detrimental effect on OS. Additionally, this approach may reduce potential neurotoxicity associated with PCI.

Publisher

Research Square Platform LLC

Reference19 articles.

1. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database;Govindan R;J Clin Oncol,2006

2. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf.

3. Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission;Aupérin A;N Engl J Med,1999

4. radiation therapy in small cell lung cancer (2020 version) Chinese Journal of Radiation Oncology|;Clinical practice guideline for;Chin J Radiat Oncol,2020

5. Detection of brain metastases from small cell lung cancer: consequences of changing imaging techniques (CT versus MRI);Seute T;Cancer,2008

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3